Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Opinion: PARP inhibitors in cancer—what do we still need to know?

1 Jul 2022

Abstract excerpt

PARP inhibitors (PARPi) have been demonstrated to exhibit profound anti-tumour activity in individuals whose cancers have a defect in the homologous recombination DNA repair pathway. Here, we describe the current consensus as to how PARPi work and how drug resistance to these agents emerges. We discuss the need to refine the current repertoire of clinical-grade companion biomarkers to be used with PARPi, so that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Integrated Circuits and Semiconductor Failure Analysis
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35892198
DOI: 10.1098/rsob.220118

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Opinion: PARP inhibitors in cancer—what do we still need to know?PMID 35892198Read ↗

Strategies for the prevention or reversal of PARP inhibitor resistance.Semantic proximity Read ↗

PARP1 roles in DNA repair and DNA replication: The basi(c)s of PARP inhibitor efficacy and resistanceSemantic proximity Read ↗

PARP inhibitors in cancer therapy: an updateSemantic proximity Read ↗

PARP inhibitors for anticancer therapySemantic proximity Read ↗

Predictive biomarkers for cancer therapy with PARP inhibitors.Semantic proximity Read ↗

Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspectiveSemantic proximity Read ↗

PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review.Semantic proximity Read ↗

Role of Biomarkers in the Development of PARP InhibitorsSemantic proximity Read ↗

The potential of PARP inhibitors in targeted cancer therapy and immunotherapySemantic proximity Read ↗

Mechanism of PARP inhibitor resistance and potential overcoming strategiesSemantic proximity Read ↗

The role of PARP in DNA repair and its therapeutic exploitationSemantic proximity Read ↗

PARP Inhibitors Resistance: Mechanisms and PerspectivesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.